Welcome to our dedicated page for PUMA BIOTECHNOLOGY news (Ticker: PBYI), a resource for investors and traders seeking the latest updates and insights on PUMA BIOTECHNOLOGY stock.
Puma Biotechnology reports developments for a biopharmaceutical company built around oncology drug commercialization and development. Company news commonly centers on NERLYNX®, its oral neratinib product for HER2-positive breast cancer, including net product revenue, cost of sales, royalty revenue and financial outlook tied to demand for the therapy.
Updates also cover alisertib, a selective, orally administered aurora kinase A inhibitor licensed for development and commercialization. Puma describes the ALISCA™-Lung1 Phase II trial in extensive-stage small cell lung cancer and the ALISCA™-Breast1 Phase II trial in HER2-negative, HR-positive metastatic breast cancer, along with employee inducement equity awards under Nasdaq Listing Rule 5635(c)(4) and investor conference activity.
Puma Biotechnology, Inc. (NASDAQ: PBYI) reported its first quarter financial results for 2024, with $40.3 million in product revenue, a net loss of $4.8 million, and $107.2 million in cash reserves. Key milestones include clinical trials for lung and breast cancer treatments. Total revenue was $43.8 million, with operating costs of $46.1 million. Second quarter and full-year 2024 financial outlook projects net product revenue of $43-45 million and $183-190 million, respectively.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.